Ceruloplasmin Protects Against Rotenone-induced Oxidative Stress and Neurotoxicity

Overview

Journal Neurochem Res

Specialties Chemistry
Neurology

Date 2011 Jun 28

PMID 21706374

Citations 12

Authors

Akiyo Hineno

Kazuma Kaneko

Kunihiro Yoshida

Shu-Ichi Ikeda

Affiliations

Soon will be listed here.

Abstract

To clarify the neuroprotective property of ceruloplasmin and the pathogenesis of aceruloplasminemia, we generated ceruloplasmin-deficient (CP⁻/⁻) mice on the C57BL/10 genetic background and further treated them with a mitochondrial complex I inhibitor, rotenone. There was no iron accumulation in the brains of CP⁻/⁻ mice at least up to 60 weeks of age. Without rotenone treatment, CP⁻/⁻ mice showed slight motor dysfunction compared with CP⁺/⁺ mice, but there were no detectable differences in the levels of oxidative stress markers between these two groups. A low dose of rotenone did not affect the mitochondrial complex I activity in our mice, however, it caused a significant change in motor behavior, neuropathology, or the levels of oxidative stress markers in CP⁻/⁻ mice, but not in CP⁺/⁺ mice. Our data support that ceruloplasmin protects against rotenone-induced oxidative stress and neurotoxicity, probably through its antioxidant properties independently of its function of iron metabolism.

Citing Articles

Human platelet lysate: a potential therapeutic for intracerebral hemorrhage.

Qiu D, Wang L, Wang L, Dong Y Front Neurosci. 2025; 18:1517601.

PMID: 39881806 PMC: 11774881. DOI: 10.3389/fnins.2024.1517601.

Empagliflozin attenuates neurodegeneration through antioxidant, anti-inflammatory, and modulation of α-synuclein and Parkin levels in rotenone-induced Parkinson's disease in rats.

Ahmed S, El-Sayed M, Kandeil M, Khalaf M Saudi Pharm J. 2022; 30(6):863-873.

PMID: 35812142 PMC: 9257853. DOI: 10.1016/j.jsps.2022.03.005.

Can the administration of platelet lysates to the brain help treat neurological disorders?.

Nebie O, Buee L, Blum D, Burnouf T Cell Mol Life Sci. 2022; 79(7):379.

PMID: 35750991 PMC: 9243829. DOI: 10.1007/s00018-022-04397-w.

Overdosing on iron: Elevated iron and degenerative brain disorders.

DMello S, Kindy M Exp Biol Med (Maywood). 2020; 245(16):1444-1473.

PMID: 32878460 PMC: 7553095. DOI: 10.1177/1535370220953065.

Assessment of the State of the Natural Antioxidant Barrier of a Body in Patients Complaining about the Presence of Tinnitus.

Pawlak-Osinska K, Kazmierczak H, Marzec M, Kupczyk D, Bilski R, Mikolajewska E Oxid Med Cell Longev. 2018; 2018:1439575.

PMID: 30510615 PMC: 6230382. DOI: 10.1155/2018/1439575.

References

Uversky V . Neurotoxicant-induced animal models of Parkinson's disease: understanding the role of rotenone, maneb and paraquat in neurodegeneration. Cell Tissue Res. 2004; 318(1):225-41. DOI: 10.1007/s00441-004-0937-z. View

Vassiliev V, Harris Z, Zatta P . Ceruloplasmin in neurodegenerative diseases. Brain Res Brain Res Rev. 2005; 49(3):633-40. DOI: 10.1016/j.brainresrev.2005.03.003. View

Bharucha K, Friedman J, Vincent A, Ross E . Lower serum ceruloplasmin levels correlate with younger age of onset in Parkinson's disease. J Neurol. 2009; 255(12):1957-62. DOI: 10.1007/s00415-009-0063-7. View

Betarbet R, Canet-Aviles R, Sherer T, Mastroberardino P, McLendon C, Kim J . Intersecting pathways to neurodegeneration in Parkinson's disease: effects of the pesticide rotenone on DJ-1, alpha-synuclein, and the ubiquitin-proteasome system. Neurobiol Dis. 2006; 22(2):404-20. DOI: 10.1016/j.nbd.2005.12.003. View

Atanasiu R, Stea D, Mateescu M, Vergely C, Dalloz F, Briot F . Direct evidence of caeruloplasmin antioxidant properties. Mol Cell Biochem. 1999; 189(1-2):127-35. DOI: 10.1023/a:1006945713860. View

Morita H, Ikeda S, Yamamoto K, Morita S, Yoshida K, Nomoto S . Hereditary ceruloplasmin deficiency with hemosiderosis: a clinicopathological study of a Japanese family. Ann Neurol. 1995; 37(5):646-56. DOI: 10.1002/ana.410370515. View

Whitnall M, Richardson D . Iron: a new target for pharmacological intervention in neurodegenerative diseases. Semin Pediatr Neurol. 2006; 13(3):186-97. DOI: 10.1016/j.spen.2006.08.008. View

Molina-Holgado F, Hider R, Gaeta A, Williams R, Francis P . Metals ions and neurodegeneration. Biometals. 2007; 20(3-4):639-54. DOI: 10.1007/s10534-006-9033-z. View

Richter F, Hamann M, Richter A . Chronic rotenone treatment induces behavioral effects but no pathological signs of parkinsonism in mice. J Neurosci Res. 2006; 85(3):681-91. DOI: 10.1002/jnr.21159. View

10.

Benarroch E . Brain iron homeostasis and neurodegenerative disease. Neurology. 2009; 72(16):1436-40. DOI: 10.1212/WNL.0b013e3181a26b30. View

11.

Kumakura K, Nomura H, Toyoda T, Hashikawa K, Noguchi T, Takeda K . Hyperactivity in novel environment with increased dopamine and impaired novelty preference in apoptosis signal-regulating kinase 1 (ASK1)-deficient mice. Neurosci Res. 2009; 66(3):313-20. DOI: 10.1016/j.neures.2009.12.003. View

12.

Zecca L, Youdim M, Riederer P, Connor J, Crichton R . Iron, brain ageing and neurodegenerative disorders. Nat Rev Neurosci. 2004; 5(11):863-73. DOI: 10.1038/nrn1537. View

13.

Healy J, Tipton K . Ceruloplasmin and what it might do. J Neural Transm (Vienna). 2007; 114(6):777-81. DOI: 10.1007/s00702-007-0687-7. View

14.

Kohno S, Miyajima H, Takahashi Y, Suzuki H, Hishida A . Defective electron transfer in complexes I and IV in patients with aceruloplasminemia. J Neurol Sci. 2000; 182(1):57-60. DOI: 10.1016/s0022-510x(00)00452-4. View

15.

Andreyev A, Kushnareva Y, Starkov A . Mitochondrial metabolism of reactive oxygen species. Biochemistry (Mosc). 2005; 70(2):200-14. DOI: 10.1007/s10541-005-0102-7. View

16.

Floris G, Medda R, Padiglia A, Musci G . The physiopathological significance of ceruloplasmin. A possible therapeutic approach. Biochem Pharmacol. 2000; 60(12):1735-41. DOI: 10.1016/s0006-2952(00)00399-3. View

17.

Starkov A . The role of mitochondria in reactive oxygen species metabolism and signaling. Ann N Y Acad Sci. 2008; 1147:37-52. PMC: 2869479. DOI: 10.1196/annals.1427.015. View

18.

Kaneko K, Hineno A, Yoshida K, Ikeda S . Increased vulnerability to rotenone-induced neurotoxicity in ceruloplasmin-deficient mice. Neurosci Lett. 2008; 446(1):56-8. DOI: 10.1016/j.neulet.2008.08.089. View

19.

Ke Y, Qian Z . Brain iron metabolism: neurobiology and neurochemistry. Prog Neurobiol. 2007; 83(3):149-73. DOI: 10.1016/j.pneurobio.2007.07.009. View

20.

Gaasch J, Lockman P, Geldenhuys W, Allen D, Van der Schyf C . Brain iron toxicity: differential responses of astrocytes, neurons, and endothelial cells. Neurochem Res. 2007; 32(7):1196-208. DOI: 10.1007/s11064-007-9290-4. View